Bristol Myers Squibb, a global biopharmaceutical company established in 1887 and headquartered in Princeton, New Jersey, is dedicated to discovering, developing, and commercializing innovative medicines across oncology, hematology, immunology, and cardiovascular diseases. With a portfolio featuring key products like Eliquis and Opdivo, the company serves healthcare providers worldwide, addressing significant unmet medical needs. As a prominent entity in the Healthcare sector's Drug Manufacturers - General industry, BMY's performance is influenced by drug development success, regulatory approvals, and patent expirations.
Bristol Myers Squibb has demonstrated a consistent pattern of beating analyst EPS estimates in its most recently reported quarters. In Q4 2025, the company reported EPS of $1.26 against an estimate of $1.13, and revenue of $12.50 billion. This followed a beat in Q3 2025, where EPS was $1.63 versus an estimate of $1.52, with revenue at $12.22 billion. Earlier in the year, Q2 2025 saw an EPS beat of $1.46 against $1.10, with revenue at $12.27 billion, and Q1 2025 reported EPS of $1.80 against an estimate of $1.50, with revenue at $11.20 billion. The company has also consistently met or exceeded revenue estimates where available, such as in Q4 2025.
Historically, Bristol Myers Squibb has shown a strong track record of exceeding analyst expectations for both earnings per share and revenue. The provided data indicates a streak of beats across the last four reported quarters, suggesting robust operational execution and successful product performance. For example, the Q4 2025 revenue of $12.50 billion exceeded the estimate of $12.40 billion, and the Q1 2026 revenue estimate stands at $10.89 billion, with Q2 2026 at $11.44 billion and Q3 2026 at $11.33 billion, pointing to significant revenue generation potential.
Recent news indicates a dynamic environment for BMY, with both positive pipeline developments and regulatory challenges. The company is expanding its oncology pipeline through a collaboration with Oxford BioTherapeutics and has seen strong initial performance from its schizophrenia drug Cobenfy. However, the FDA's second rejection of Replimune's immunotherapy RP1, intended for combination with BMY's Opdivo, presents a setback. Analyst sentiment is mixed, with Cantor Fitzgerald raising its price target to $54 (Neutral) while Guggenheim reiterates a Buy rating with a $72 price target.
Moving forward, investors will be closely monitoring the Q1 2026 earnings report for insights into the projected year-over-year decline in profitability and management's outlook. Key watch points include the strategic implications of the regulatory setback for RP1, the continued performance and market penetration of Cobenfy, and the progress of new collaborations like the one with Oxford BioTherapeutics. The company's ability to navigate patent cliffs and leverage its pipeline will be crucial for future growth.
